The use of vaptans in clinical endocrinology

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 4, 2013, Pages 1321-1332

  Peri, Alessandro ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; BARBITURIC ACID DERIVATIVE; CONIVAPTAN; DIGOXIN; DILTIAZEM; FUROSEMIDE; KETOCONAZOLE; LIXIVAPTAN; MACROLIDE; MOZAVAPTAN; PLACEBO; RIFAMPICIN; RWJ 351647; SATAVAPTAN; SPIRONOLACTONE; TOLVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR; BENZAZEPINE DERIVATIVE; HORMONE ANTAGONIST; VASOPRESSIN RECEPTOR;

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; COST OF ILLNESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINOLOGY; FEVER; FLUID BALANCE; GRAPEFRUIT JUICE; HUMAN; HYPERVOLEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOVOLEMIA; INAPPROPRIATE VASOPRESSIN SECRETION; KIDNEY POLYCYSTIC DISEASE; LIVER CIRRHOSIS; LIVER METABOLISM; LOADING DRUG DOSE; NAUSEA; NONHUMAN; OPTIMAL DRUG DOSE; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL; STRUCTURE ACTIVITY RELATION; THIRST; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; WATER DEPRIVATION; XEROSTOMIA; BIOLOGICAL MODEL; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; DRUG DEVELOPMENT; EVALUATION; METHODOLOGY; REVIEW; SYNTHESIS;

BENZAZEPINES; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; ENDOCRINOLOGY; HORMONE ANTAGONISTS; HUMANS; HYPONATREMIA; INAPPROPRIATE ADH SYNDROME; MODELS, BIOLOGICAL; RECEPTORS, VASOPRESSIN;

MLCS; MLOWN;

EID: 84876270922     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-4082     Document Type: Article

References (101)

1. Hoorn EJ, Lindemans J, Zietse R. Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management. Nephrol Dial Transplant. 2006;21:70-76.
2. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med. 2007;356:2064-2072.
3. Zilberberg MD, Exuzides A, Spalding J, et al. Epidemiology, clinical and economic outcomes of admission hyponatremia among hospitalized patients. Curr Med Res Opin. 2008;24:1601-1608.
4. Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med. 2009; 122:857-865.
5. Wald R, Jaber BR, Price LL, Upadhyay A, Madias NE. Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med. 2010;170:294-302.
6. Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med. 2006;119:71.e1-e8.
7. Miyazaki T, Ohmoto K, Hirose T, Fujiki H. Chronic hyponatremia impairs memory in rats: effects of vasopressin antagonist tolvaptan. J Endocrinol. 2010;206:205-211.
8. Kinsella S, Moran S, Sullivan MO, Molloy MG, Eustace JA. Hyponatremia independent of osteoporosis is associated with fracture occurrence. Clin J Am Soc Nephrol. 2010;5:275-280.
9. Verbalis JG, Barsony J, Sugimura Y, et al. Hyponatremia-induced osteoporosis. J Bone Miner Res. 2010;25:554-563.
10. Barsony J, Sugimura Y, Verbalis JG. Osteoclast response to low extracellular sodium and the mechanism of hyponatremia-induced bone loss. J Biol Chem. 2011;25:10864-10875.
11. Barsony J, Manigrasso MB, Xu Q, Tam H, Verbalis JG. 2012 Chronic hyponatremia exacerbates multiple manifestations of senescence in male rats. Age (Dordr). Published Online: January 5, 2012 (doi:10.1007/s11357-011-9347-9).
12. Dasta JF, Chiong JR, Christian R, et al. Updateon tolvaptan for the treatment of hyponatremia. Expert Rev Pharmacoecon Outcomes Res. 2012;12:399-410.
13. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med. 2007;120:S1-S21.
14. Peri A, Pirozzi N, Parenti G, Festuccia F, Menè P. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Endocrinol Invest. 2010;33:671-682.
15. Peri A, Combe C. Considerations regarding the management of hyponatraemia secondary to SIADH. Best Pract Res Clin Endocrinol Metab. 2012;26:S16-S26.
16. Goldberg M. Hyponatremia. Med Clin North Am. 1981;65:251-269.
17. Oliver G, Schäfer EA. On the physiological action of extracts of pituitary body and certain other glandular organs: preliminary communication. J Physiol. 1895;18:277-279.
18. Howell WH. The physiological effects of extracts of the hypophysis cerebri and infundibular body. J Exp Med. 1898;3:245-258.
19. Farini F. Diabete insipido ed opoterapia. Gazz Osped Clin. 1913; 34:1135-1139.
20. Von Den Velden R. Die Nierenvirkung von Hypophysenextracten beim Menschen. Berl Klin Wochenschr. 1913;50:2083-2086.
21. Turner RA, Pierce JG, du Vigneaud V. The purification and the amino acid content of vasopressin preparations. J Biol Chem. 1951;191:21-28.
22. du Vigneaud V, Gash DT, Katsoyannis PG. Asynthetic preparation possessing biological properties associated with arginine-vasopressin. J Am Chem Soc. 1954;76:4751-4752.
23. Chan WY, Hruby VJ, Flouret G, du Vigneuad V. 4-Leucine-oxytocin: natriuretic, diuretic, and antivasopressin polypeptide. Science. 1968;161:280-281.
24. Chan WY, du Vigneaud V. Natriuretic, diuretic and anti-arginine- vasopressin (ADH) effects of two analogs of oxytocin: [4-leucine]-oxytocin and [2,4-diisoleucine]-oxytocin. J Pharmacol Exp Ther. 1970;174:541-549.
25. Kinter LB, Huffman WF, Stassen FL. Antagonists of the antidiuretic activity ofvasopressin. Am J Physiol. 1988;254:F165-F177.
26. Allison NL, Albrightson-Winslow CR, Brooks DP, et al. 1988 Species heterogeneity and antidiuretic hormone antagonists: what are the predictors? In: Cowley AW, Liard JF, Ausiello DA, eds. Vasopressin: Cellular and Integrative Functions. New York: Raven Press Ltd.; 207-214.
27. Brooks DP, Koster PF, Albrightson-Winslow CR, Stassen FL, Huffman WF, Kinter LB. SK&F 105494 is a potent antidiuretic hormone antagonist in the rhesus monkey (Macaca mulatta). J Pharmacol Exp Ther. 1988;245:211-215.
28. Mah SC, Hofbauer KG. Evaluation of the pharmacologic properties of a vasopressin antagonist in Brattleboro rats. J Pharmacol Exp Ther. 1988;245:1028-1032.
29. Albrightson-Winslow CR, Caldwell N, Brooks DP, Huffman WF, Stassen FL, Kinter LB. Cyclooxygenase inhibition unmasks the full antidiuretic agonist activity of the vasopressin antagonist, SK&F 101926, in dogs. J Pharmacol Exp Ther. 1989;249:366-371.
30. Yamamura Y, Ogawa H, Chihara T, et al. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science. 1991;252:572-574.
31. 2 receptor antagonist. Br J Pharmacol. 1992; 105:787-791.
32. Ohnishi A, Orita Y, Okahara R, et al. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J Clin Invest. 1993;92:2653-2659.
33. Serradeil-Le Gal C, Wagnon J, Garcia C, et al. Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J Clin Invest. 1993;92:224-231.
34. Freidinger RM, Pettibone DJ. Small molecule ligands for oxytocin and vasopressin receptors. Med Res Rev. 1997;17:1-16.
35. Tahara A, Tomura Y, Wada KI, et al. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther. 1997;282:301-308.
36. Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860-867.
37. de Goma EM, Vagelos RH, Fowler MB, Ashley EA. Emerging therapies for the management of decompensated heart failure: from bench to bedside. J Am Coll Cardiol. 2006;48:2397-2409.
38. Robertson GL. Vaptans for the treatment of hyponatremia. Nat Rev Endocrinol. 2011;7:151-161.
39. Ghali JK, Koren MJ, Taylor JR, et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab. 2006; 91:2145-2152.
40. Annane D, Decaux G, Smith N; Conivaptan Study Group. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am J Med Sci. 2009;337: 28-36.
41. Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N; Conivaptan Study Group. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol. 2007;27:447-457.
42. Wong F, Blei AT, Blendis LM, Thuluvath PJA. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology. 2003;37:182-191.
43. Schrier RW, Gross P, Gheorghiade M, et al; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099-2112.
44. Berl T, Quittnat-Pelletier F, Verbalis JG, et al; SALTWATER Investigators. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010;21:705-712.
45. Gheorghiade M, Gottlieb SS, Udelson JE, et al; Tolvaptan Investigators. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol. 2006;97:1064-1067.
46. Feldman BJ, Rosenthal SM, Vargas GA, et al. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med. 2005;352: 1884-1890.
47. Soupart A, Gross P, Legros JJ, et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol. 2006;1:1154-1160.
48. Verbalis JG, Zeltser D, Smith N, Barve A, Andoh M. Assessment of the efficacy and safetyofintravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. Clin Endocrinol (Oxf). 2008;69:159-168.
49. Yamaguchi K, Shijubo N, Kodama T, et al; Ectopic ADH Syndrome Therapeutic Research Group. Clinical implication of the antidiuretic hormone (ADH) receptor antagonist mozavaptan hydrochloride in patients with ectopic ADH syndrome. Jpn J Clin Oncol. 2011;41:148-152.
50. Kenz S, Haas CS, Werth SC, Bohnet S, Brabant G. High sensitivity to tolvaptan in paraneoplastic syndrome of inappropriate ADH secretion (SIADH). Ann Oncol. 2011;22:2696.
51. Verbalis JG, Adler S, Schrier RW, Berl T, Zhao Q, Czerwiec FS; SALT Investigators. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol. 2011;164:725-732.
52. Soupart A, Coffernils M, Couturier B, Gankam-Kengne F, Decaux G. Efficacy and tolerance of urea compared with vaptans for longterm treatment of patients with SIADH. Clin J Am Soc Nephrol. 2012;7:742-747.
53. Decaux G. Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am J Med. 2001;110: 582-584.
54. Gheorghiade M, Niazi I, Ouyang J, et al; Tolvaptan Investigators. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results fromadouble-blind, randomized trial. Circulation. 2003;107:2690-2696.
55. Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol. 2006;47:1615-1621.
56. Rossi J, Bayram M, Udelson JE, et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card Care. 2007;9:82-86.
57. Konstam MA, Gheorghiade M, Burnett JC Jr, et al; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297:1319-1331.
58. Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001;104:2417-2423.
59. Udelson JE, Orlandi C, Ouyang J, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol. 2008;52:1540-1545.
60. Pang PS, Gheorghiade M, Dihu J, et al. Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonisminheart failure outcome study with tolvaptan (EVEREST) trials. Am Heart J. 2011;161:1067-1072.
61. Vaduganathan M, Gheorghiade M, Pang PS, et al; EVEREST Investigators. Efficacyoforal tolvaptaninacute heart failure patients with hypotension and renal impairment. J Cardiovasc Med (Hagerstown). 2012;13:415-422.
62. Aronson D, Verbalis JG, Mueller M, Krum H; DILIPO investigators. Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study. Eur J Heart Fail. 2011;13:327-336.
63. Matsuzaki M, Hori M, Izumi T, Asanoi H, Tsutamoto T; Tolvaptan Investigators. Effects of tolvaptan on volume overload in Japanese patients with heart failure: results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Cardiovasc Drugs Ther. 2011;25(suppl 1):S19-S31.
64. Matsuzaki M, Hori M, Izumi T, Fukunami M; Tolvaptan Investigators. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: aphase III, randomized, double-blind, placebocontrolled study (QUEST study). Cardiovasc Drugs Ther. 2011; 25(suppl 1):S33-S45.
65. Inomata T, Izumi T, Matsuzaki M, Hori M, Hirayama A; Tolvaptan Investigators. Phase III clinical pharmacology study of tolvaptan. Cardiovasc Drugs Ther. 2011;25(suppl 1):S57-S65.
66. Goldsmith SR, Gilbertson DT, Mackedanz SA, Swan SK. Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure. J Card Fail. 2011;17:982-989.
67. Udelson JE, Bilsker M, Hauptman PJ, et al. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide inpatients with heart failure and systolic dysfunction. J Card Fail. 2011;17:973-981.
68. Inoue T, Ohnishi A, Matsuo A, et al. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis. Clin Pharmacol Ther. 1998;63:561-570.
69. Guyader D, Patat A, Ellis-Grosse EJ, Orczyk GP. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology. 2002;36:1197-1205.
70. Ginès P, Wong F, Watson H, et al; NormoCAT Study Investigators. Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascitesinpatients with cirrhosis without hyponatraemia - a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2010;31:834-845.
71. Wong F, Gines P, Watson H, et al. Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol. 2010;53:283-290.
72. Okita K, Sakaida I, Okada M, et al. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis. J Gastroenterol. 2010;45:979-987.
73. Wong F, Watson H, Gerbes A, et al; Satavaptan Investigators Group. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum ofascites severity. Gut. 2012; 61:108-116.
74. Ginès P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D; HypoCAT Study Investigators. Effects of satavaptan, aselective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology. 2008;48:204-213.
75. Cárdenas A, Ginès P, Marotta P, et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J Hepatol. 2012;56:571-578.
76. Verbalis JG, Hoorn EJ. The use of analgorithm to aid diagnosis and treatment of patients with hyponatraemia secondary to SIADH. In: Program of the 12th European Congress of Endocrinology; April 24-28, 2010; Prague, Czech Republic. Abstract P209.
77. Furst H, Hallows KR, Post J, et al. The urine/plasma electrolyte ratio: a predictive guide to water restriction. Am J Med Sci. 2000; 319:240-244.
78. Castillo JJ, Vincent M, Justice E. Diagnosis and management of hyponatremia in cancer patients. Oncologist. 2012;17:756-765.
79. Hansen O, Sørensen P, Hansen KH. The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period. Lung Cancer. 2010;68:111-114.
80. Sørensen JB, Andersen MK, Hansen HH. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med. 1995;238:97-110.
81. Kirch C, Gachot B, Germann N, Blot F, Nitenberg G. Recurrent ifosfamide-induced hyponatraemia. Eur J Cancer. 1997;33:2438-2439.
82. Kleta R, Wagner A, Jürgens H. Recurrence of SIADH after a highdose regimen of thiotepa, carboplatin, and etoposide phosphate. Med Pediatr Oncol. 1998;31:129.
83. Friedman B, Cirulli J. Hyponatremia in critical care patients: frequency, outcome, characteristics, and treatment with the vasopressin V(2)-receptor antagonist tolvaptan. J Crit Care. Published Online: August 8, 2012 (doi:10.1016/j.jcrc.2012.06.001).
84. Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med. 2000; 342:1581-1589.
85. Berl T. Treating hyponatremia: damnedifwedoand damnedifwe don't. Kidney Int. 1990;37:1006-1018.
86. Velez JC, Dopson SJ, Sanders DS, Delay TA, Arthur JM. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience. Nephrol Dial Transplant. 2010;25:1524-1531.
87. Shoaf SE, Bricmont P, Mallikaarjun S. Effects of CYP3A4 inhibition and inductiononthe pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. Br J Clin Pharmacol. 2012;73:579-587.
88. Shoaf SE, Mallikaarjun S, Bricmont P. Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist, inhealthy subjects. EurJClin Pharmacol.2012; 68:207-211.
89. Shoaf SE, Elizari MV, Wang Z, et al. Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias. J Cardiovasc Pharmacol Ther. 2005;10: 165-171.
90. Shoaf SE, Ohzone Y, Ninomiya S, et al. In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxinin healthy subjects. J Clin Pharmacol. 2011;51:761-769.
91. Callahan MA, Do HT, Caplan DW, Yoon-Flannery K. Economic impact of hyponatremia in hospitalized patients: a retrospective cohort study. Postgrad Med. 2009;121:186-191.
92. Shea AM, Hammill BG, Curtis LH, Szczech LA, Schulman KA. Medical costsofabnormal serum sodium levels. J Am Soc Nephrol. 2008;19:764-770.
93. Shorr AF, Tabak YP, Johannes RS, Gupta V, Saltzberg MT, Costanzo MR. Burden of sodium abnormalities in patients hospitalized for heart failure. Congest Heart Fail. 2011;17:1-7.
94. Cyr PL, Slawsky KA, Olchanski N, et al. Effect of serum sodium concentration and tolvaptan treatmenton length of hospitalization in patients with heart failure. Am J Health Syst Pharm. 2011;68: 328-333.
95. Dasta JF, Chiong JR, Christian R, Lin J. Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction amongUS patients with the syndrome of in appropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials. Hosp Pract (Minneap). 2012;40:7-14.
96. Chiong JR, Kim S, Lin J, Christian R, Dasta JF. Evaluation of costs associated with tolvaptan-mediated length-of-stay reduction among heart failure patients with hyponatremiainthe US, based on the EVEREST trial. J Med Econ. 2012;15:276-284.
97. Gross PA, Wagner A, Decaux G. Vaptans are not the mainstay of treatment in hyponatremia: perhaps not yet. Kidney Int. 2011;80: 594-600.
98. Gattone VHII, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003;9:1323-1326.
99. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH II. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med. 2004;10:363-364.
100. Wang X, Wu Y, Ward CJ, Harris PC, Torres VE. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol. 2008;19:102-108.
101. Torres VE, Chapman AB, Devuyst O, et al; the TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407-2418.